Scan with a marker to find certain slow-growing tumors
Part of Cancer clinical trials.
This study tests an imaging scan using a special tracer (68Ga-HA-DOTATATE) to look for tumors that have somatostatin receptors. It may help doctors better locate suspected tumor sites so treatment planning can be more accurate.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a known or suspected tumor that reacts to somatostatin, such as some neuroendocrine tumors, pheochromocytoma, paraganglioma, or medullary thyroid cancer
- You can have a CT or MRI done within 6 months before joining the study
- You (or a legal decision-maker) can sign a consent form and agree to take part
- You can safely fit on the PET/CT scanner (weight must be 225 kg or less)
- You can complete the scan by lying still, and severe claustrophobia would prevent participation
- You should not have had an allergic reaction to DOTATATE or similar “somatostatin” medicines, and you need working vein access for an IV
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of PET scan using a radioactive tracer called 61Cu-NODAGA-LM3 to detect neuroendocrine tumors (NETs). The goal is to see if it works as well as or better than the standard scan. If you have a NET and need a scan for staging or treatment planning, you might be able to join.
This pilot study tests a total-body PET scan with approved tracer medicines to help detect cancer spread in people with suspected metastatic prostate cancer or certain neuroendocrine tumors (NETs). You may be able to join if recent scans already suggest metastasis and you can safely complete the scan timing and positioning.
This trial tests how well a special scan (Ga-68 DOTATATE PET combined with MRI) helps diagnose and guide treatment for certain brain tumors that have somatostatin receptors. It may help doctors better find tumor recurrence or remaining tumor after treatment.
This study uses a PET/CT scan with a small amount of radioactive tracer to see how neuroendocrine tumors are behaving in adults. It may help doctors better detect and evaluate these tumors, especially when symptoms suggest a carcinoid-type hormone problem.
This study tests a special PET scan called 68Ga-DOTATOC to see if it can find certain breast cancer cells in the body. It may help doctors better understand your cancer, especially if it has spread to the liver or bones.
This trial tests a new PET scan tracer to find neuroendocrine tumors in the body. It may help doctors see where the tumors are and plan better treatment.
Hear when a new Neuroendocrine Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.